Home › Research › How common it is
Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study
Edmund Chi Lok Cheung, Matthew Adesuyan, Máté Szilcz, Lisa M. Kalisch Ellett, Sonia H Shah, Yogini Hariprasad Jani, Sara Hägg, Nicole L. Pratt et al.. Age and Ageing, 2025-04-28
Topic: Risk, prevention and care in population studies
Plain-language summary
One million nine hundred twenty-five thousand, five hundred sixty-three individuals were included across the four databases with a median follow-up ranging from 5.6 to 8.4 years. Compared to ACEI, initiation with ARB was associated with a reduced risk of incident all-cause dementia [hazard ratio (HR): 0.92, 95% confidence interval (CI): 0.89-0.94] and VaD (HR 0.87, 95% CI 0.78-0.96) but not AD. This is the largest multinational cohort study conducted to date investigating different classes of antihypertensive drugs and the risk of incident dementia. When initiating antihypertensives, physicians and patients should consider the reduced risk of all-cause dementia and VaD with ARB compared with ACEI in their risk-benefit assessment.
What this study adds
Evidence grade: High
This is a pooled review. In this large multinational cohort, starting an ARB was associated with a reduced risk of all-cause dementia and vascular dementia compared with starting an ACEI, but not with a reduced risk of Alzheimer's disease. Reported effect size: HR 0.87.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Cheung, E. C. L., Adesuyan, M., Szilcz, M., Ellett, L. M. K., Shah, S. H., Jani, Y. H., et al. (2025). Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study. Age and Ageing. https://doi.org/10.1093/ageing/afaf121
Vancouver
Cheung ECL, Adesuyan M, Szilcz M, Ellett LMK, Shah SH, Jani YH, et al. Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study. Age and Ageing. 2025. doi:10.1093/ageing/afaf121. PMID: 40413804.
BibTeX
@article{cheung2025-40413804,
author = {Cheung, Edmund Chi Lok and Adesuyan, Matthew and Szilcz, Máté and Ellett, Lisa M. Kalisch and Shah, Sonia H and Jani, Yogini Hariprasad and Hägg, Sara and Pratt, Nicole L. and others},
title = {{Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study}},
journal = {Age and Ageing},
year = {2025},
doi = {10.1093/ageing/afaf121},
pmid = {40413804},
url = {https://doi.org/10.1093/ageing/afaf121}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- One million nine hundred twenty-five thousand, five hundred sixty-three individuals were included across the four databases with a median follow-up ranging from 5.6 to 8.4 years.
- Compared to ACEI, initiation with ARB was associated with a reduced risk of incident all-cause dementia [hazard ratio (HR): 0.92, 95% confidence interval (CI): 0.89-0.94] and VaD (HR 0.87, 95% CI 0.78-0.96) but not AD.
- This is the largest multinational cohort study conducted to date investigating different classes of antihypertensive drugs and the risk of incident dementia.
- When initiating antihypertensives, physicians and patients should consider the reduced risk of all-cause dementia and VaD with ARB compared with ACEI in their risk-benefit assessment.
Why it matters
In this large multinational cohort, starting an ARB was associated with a reduced risk of all-cause dementia and vascular dementia compared with starting an ACEI, but not with a reduced risk of Alzheimer's disease. The authors suggest physicians and patients consider this in risk-benefit assessment when initiating antihypertensives.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Study designmeta-analysis
- Effect sizeHR 0.87
- Evidence strengthHigh
How this study scored 64/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for sample size and studied in people because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Age and Ageing) |
| Journal's citation record | 2 / 4 | Age and Ageing: journal h-index 231 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 2 / 7 | Cited 14 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 8.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 14 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Celine Sze Ling Chui: h-index 39 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 11 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40413804) |
| Free to read | 2 / 2 | Free to read |
| Total | 64 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in How common it is from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.